Obesity

Semaglutide cut the risk for worsening heart failure and CV death for adults with HF with preserved ejection fraction, according to data presented at the European Society of Cardiology Congress and simultaneously published in The Lancet.

In an analysis of deaths of patients with obesity but not diabetes from the SELECT trial, those assigned semaglutide 2.4 mg had reduced risk for death from COVID-19 compared with those assigned placebo.

Obesity medications were prescribed to very few Military Health System beneficiaries between October 2017 and September 2022, according to a study published in Obesity.

Managing obesity involves a well-rounded approach, often including lifestyle modifications and, in many cases, pharmacotherapy. Understanding the role of anti-obesity medications is crucial in this context.

Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study.

An intermittent calorie restriction diet was “safe and more effective” in reducing hepatic steatosis at 12 weeks vs. a standard of care diet in metabolic dysfunction-associated steatotic liver disease, particularly among those with obesity.

GLP-1 receptor agonist use on top of SGLT2 inhibition in patients with HF with preserved ejection fraction, type 2 diabetes and obesity was associated with reduced risk for adverse events vs. SGLT2 inhibition alone, researchers reported.

Analyses of people with early-onset colorectal cancer showed those who lived in rural areas had greater 5-year disease-related mortality risk than those who lived in nonrural areas, according to results of a retrospective study.

Gaining weight can raise the risk for atopic dermatitis and possibly other immune-mediated skin diseases in children, whereas losing weight can reduce this risk, according to a study.